Abstract 590P
Background
KRAS mutations are the most common molecular alteration in NSCLC, with the KRAS G12C variant reported in 12-13% of Western patients. We sought to determine the prevalence and characteristics of Australian pts with advanced NSCLC harbouring the KRAS G12C mutation.
Methods
We performed a multi-centre, retrospective review of pts diagnosed with advanced NSCLC in 2018 - 2019 for whom a KRAS result was available. Comprehensive clinicopathological and outcome data was collected and analysed for all KRAS G12C patients, and subsets of pts with non-G12C mutations (KRAS other) and KRAS wild type (KRAS WT).
Results
1085 pts from 17 sites were included, of whom 189 (17.4%) were KRAS G12C. Comprehensive data was collected on 163 KRAS G12C, 116 KRAS other and 104 KRAS WT pts. Baseline characteristics are summarised in the table. The 3 cohorts were similar in terms of age, sex, ECOG and metastatic disease at diagnosis. The KRAS G12C cohort had fewer never smokers (p <0.0001) and a trend to more PDL1 ≥50% patients (p=0.10) than the KRAS WT cohort. Comparable proportions in each cohort received any systemic therapy or any immunotherapy for advanced disease, with a similar number of lines of therapy delivered. Only 3 KRAS G12C patients received targeted therapy because of limited access. Median overall survival (mOS) in the KRAS G12Ccohort was 11.9 months (mo), compared to 17.0 mo in the KRAS other cohort (p=0.34), 26.8 mo in the KRAS WTcohort (p=0.02) and 17.6 mo in the KRAS WT cohort with EGFR/ALK/ROS1 mutated patients excluded (p=0.17). Table: 590P
KRAS G12C(n=163) | KRAS other (n=116) | KRAS WT(n=104) | All patients (n=383) | |
Age at diagnosis, years (range) | 66 (42-92) | 68 (41-89) | 69 (29-88) | 67 (29-92) |
Sex, n (%) | ||||
• Male | 84 (52) | 66 (57) | 61 (59) | 211 (55) |
• Female | 79 (48) | 50 (43) | 43 (41) | 172 (45) |
ECOG, n (%) | ||||
• 0-1 | 116 (71) | 81 (70) | 77 (74) | 274 (72) |
• 2+ | 23 (14) | 17 (15) | 9 (9) | 49 (13) |
• NA | 24 (15) | 18 (16) | 18 (17) | 60 (16) |
Smoking status, n (%) | ||||
• Current / past | 153 (94) | 107 (92) | 76 (73) | 336 (88) |
• Never | 3 (2) | 7 (6) | 21 (20) | 31 (8) |
• NA | 7 (4) | 2 (2) | 7 (7) | 16 (4) |
PDL1 result, n (%) | ||||
• <1% | 24 (15) | 17 (15) | 21 (20) | 62 (16) |
• 1-49% | 45 (28) | 42 (36) | 30 (29) | 117 (31) |
• ≥50% | 59 (36) | 39 (34) | 27 (26) | 125 (33) |
• Unknown | 35 (21) | 18 (16) | 26 (25) | 79 (21) |
Metastasis at diagnosis, n (%) | 137 (84) | 97 (84) | 86 (83) | 320 (84) |
Conclusions
Our study demonstrated a prevalence of KRAS G12C mutations of 17.4% among Australian pts with advanced NSCLC. The KRAS G12C, KRAS other and KRAS WT cohorts had similar patient and treatment patterns, although smoking history was more common in pts with a KRAS mutation. In the absence of other key driver mutations, there was no significant difference in mOS between cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Walter and Eliza Hall Institute of Medical Research.
Funding
Amgen.
Disclosure
B. Markman: Financial Interests, Personal, Advisory Board: Amgen, Merck, Bristol Myers Squibb, BeiGene, AstraZeneca; Financial Interests, Institutional, Research Funding: Amgen. B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. L.M. Nott: Financial Interests, Institutional, Research Funding: Roche, Servier; Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck, Roche, Pfizer, MSD, Servier, Ipsen, AstraZeneca, Novartis; Financial Interests, Personal, Other, Honorarium: MSD, Amgen, Roche, Bristol Myers Squibb, Celgene. R. Roberts-Thomson: Financial Interests, Personal, Advisory Board: Bristol Myer Squibbb, Merck Sharpe and Dohme, Pfizer, AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol Myer Squibbb, Merck Sharpe and Dohme, Novartis, AstraZeneca, Pierre Fabre. B. Hughes: Financial Interests, Personal, Advisory Board: MSD, BMS, Pfizer, Roche, AstraZeneca, Takeda, Sanofi, Esai, Amgen; Financial Interests, Institutional, Research Funding: Amgen. N. Pavlakis: Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, AstraZeneca, Takeda, Pfizer, Roche, Amgen, BeiGene; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, Pfizer, Roche, Takeda, Pierre-Faber, Illumina, Bayer; Financial Interests, Institutional, Research Funding: Bayer, Pfizer, Roche. S. Parakh: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, Roche, AstraZeneca; Financial Interests, Institutional, Research Funding: Bayer, Roche. D. Brungs: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD. S.E. Bowyer: Financial Interests, Personal, Advisory Board: Lilly, Ipsen, Sanofi, MSD, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Sanofi. L. Warburton: Financial Interests, Personal, Advisory Board: Roche, Novartis, MSD, AstraZeneca, Bristol Myers Squibb. S.J. Harris: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb. S. Ramanujam: Financial Interests, Personal, Full or part-time Employment, Until April 2023: Amgen. A. Wang: Financial Interests, Personal, Full or part-time Employment: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract